IN2012DN02556A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02556A IN2012DN02556A IN2556DEN2012A IN2012DN02556A IN 2012DN02556 A IN2012DN02556 A IN 2012DN02556A IN 2556DEN2012 A IN2556DEN2012 A IN 2556DEN2012A IN 2012DN02556 A IN2012DN02556 A IN 2012DN02556A
- Authority
- IN
- India
- Prior art keywords
- amide
- salt
- ester
- solvate
- provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
Abstract
The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0917576A GB0917576D0 (en) | 2009-10-07 | 2009-10-07 | Novel estrogenreceptor ligands |
GBGB1011859.4A GB201011859D0 (en) | 2010-07-14 | 2010-07-14 | Novel estrogen receptor ligands |
PCT/EP2010/064941 WO2011042475A1 (en) | 2009-10-07 | 2010-10-06 | Substituted pyrazoles as estrogen receptor ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN02556A true IN2012DN02556A (en) | 2015-08-28 |
Family
ID=43856389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2556DEN2012 IN2012DN02556A (en) | 2009-10-07 | 2010-10-06 |
Country Status (10)
Country | Link |
---|---|
US (2) | US8653112B2 (en) |
EP (1) | EP2486018B1 (en) |
JP (1) | JP5735518B2 (en) |
CN (1) | CN102648183B (en) |
AR (2) | AR078536A1 (en) |
DK (1) | DK2486018T3 (en) |
ES (1) | ES2737429T3 (en) |
IN (1) | IN2012DN02556A (en) |
TW (2) | TW201124409A (en) |
WO (2) | WO2011042477A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
CA2856946C (en) | 2011-12-02 | 2016-08-02 | Phenex Pharmaceuticals Ag | Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmunediseases |
CN102558058B (en) * | 2012-01-19 | 2014-10-29 | 陕西理工学院 | 1-aryl-3-substituent-5-substituted amino-4-pyrazole formamide compound and application thereof |
JO3215B1 (en) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | Carboxamide or Sulfonamide Substituted Nitrogen-Containing 5-Membered Heterocycles as Modulators for the Orphan Nuclear Receptor RORy |
US9944597B2 (en) | 2013-09-16 | 2018-04-17 | The Board Of Regents Of The University Of Texas System | Polysubstituted pyrroles having microtubule-disrupting, cytotoxic and antitumor activities and methods of use thereof |
WO2015070366A1 (en) * | 2013-11-12 | 2015-05-21 | Merck Sharp & Dohme Corp. | Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
WO2015082643A1 (en) | 2013-12-05 | 2015-06-11 | Karo Bio Ab | Estrogen receptor beta agonists for use in treating mesothelioma |
CN104974091B (en) * | 2014-04-10 | 2018-01-02 | 沈阳药科大学 | Diaryl pyrazole azole compound of 3 methyl 1,5 and its production and use |
WO2016036721A1 (en) | 2014-09-02 | 2016-03-10 | The Regents Of The University Of California | Estrogen receptor ligand treatment for neurodegenerative diseases |
WO2016097036A1 (en) * | 2014-12-17 | 2016-06-23 | Karo Bio Ab | Estrogen receptor ligand for use in treating melanoma |
CN106397377B (en) * | 2016-09-05 | 2019-04-05 | 中南大学 | The method of fluorine on a kind of electron rich five-ring heterocycles acid and its derivative decarboxylation |
JP7142406B2 (en) | 2017-05-09 | 2022-09-27 | カインド ファーマシューティカル | Indolizine derivative and its medical application |
CN108610246A (en) * | 2018-06-01 | 2018-10-02 | 山东潍坊润丰化工股份有限公司 | A kind of Cyproconazole intermediate 1-(4- chlorphenyls)The preparation method of -2- cyclopropyl -1- acetone |
WO2021057998A1 (en) * | 2019-09-29 | 2021-04-01 | 上海森辉医药有限公司 | Preparation method for pyrroloaminopyridazinone compound |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5726653A (en) * | 1980-05-09 | 1982-02-12 | Ciba Geigy Ag | Substituted phenyl ether |
JPS58208275A (en) * | 1982-05-20 | 1983-12-03 | Lion Corp | 5-amino-pyrazole derivative and antitumor agent containing it |
US5096919A (en) * | 1989-01-05 | 1992-03-17 | Ciba-Geigy Corporation | Pyrrolylphenyl-substituted hydroxamic acid derivatives |
EP0839808A1 (en) * | 1996-10-29 | 1998-05-06 | Novartis AG | Pyrazole derivatives, processes for their preparation, and their use as herbicides |
ES2281186T3 (en) | 1998-08-07 | 2007-09-16 | Novartis Vaccines And Diagnostics, Inc. | PIRAZOLES AS MODULATORS OF RECEPTORS OF STROGENS. |
AU1199600A (en) * | 1998-10-02 | 2000-04-26 | Board Of Trustees Of The University Of Illinois, The | Estrogen receptor ligands |
US6911468B2 (en) * | 2000-05-22 | 2005-06-28 | Takeda Chemical Industries, Ltd. | Tyrosine phosphatase inhibitors |
AU2002356301A1 (en) * | 2001-12-21 | 2003-07-15 | Cancer Research Technology Ltd. | 3,4-diarylpyrazoles and their use in the therapy of cancer |
US6835745B2 (en) * | 2002-01-15 | 2004-12-28 | Wyeth | Phenyl substituted thiophenes as estrogenic agents |
GB0229618D0 (en) * | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
DK1633699T3 (en) * | 2003-05-16 | 2007-03-26 | Wyeth Corp | Aryl-carbaldehydroxime derivatives and their use as estrogenic agents |
US7250440B2 (en) * | 2003-08-12 | 2007-07-31 | Wyeth | (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents |
US20070191336A1 (en) | 2003-12-24 | 2007-08-16 | Flynn Daniel L | Anti-inflammatory medicaments |
CN101061116A (en) | 2004-09-24 | 2007-10-24 | 詹森药业有限公司 | Sulfonamide compounds |
JP2006316054A (en) * | 2005-04-15 | 2006-11-24 | Tanabe Seiyaku Co Ltd | High-conductance type calcium-sensitive k channel opening agent |
JP2006306755A (en) | 2005-04-27 | 2006-11-09 | Nippon Kayaku Co Ltd | New pyrazole derivative and hsp90 inhibitor containing the same as active ingredient |
EP1889617A1 (en) | 2006-07-11 | 2008-02-20 | Freie Universität Berlin | Triphenyl modified 5-membered heterocycles and their use as anticancer and antiflammatory agents |
EP2074102A1 (en) | 2006-10-13 | 2009-07-01 | Karo Bio Ab | 2-phenyl indene derivatives useful as estrogen receptor ligands |
WO2009012954A1 (en) | 2007-07-20 | 2009-01-29 | Karo Bio Ab | Novel estrogen receptor ligands |
CA2695812A1 (en) | 2007-08-08 | 2009-02-12 | Neurosearch A/S | Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
GB0806656D0 (en) | 2008-04-11 | 2008-05-14 | Karobio Ab | Novel estrogen receptor ligands |
RU2492164C2 (en) | 2008-04-16 | 2013-09-10 | Каро Био Аб | Novel ligands of estrogen receptors |
GB0817221D0 (en) | 2008-09-19 | 2008-10-29 | Karobio Ab | Novel estrogen receptor ligands |
-
2010
- 2010-10-06 EP EP10760729.3A patent/EP2486018B1/en not_active Not-in-force
- 2010-10-06 WO PCT/EP2010/064944 patent/WO2011042477A1/en active Application Filing
- 2010-10-06 US US13/500,341 patent/US8653112B2/en not_active Expired - Fee Related
- 2010-10-06 DK DK10760729.3T patent/DK2486018T3/en active
- 2010-10-06 JP JP2012532583A patent/JP5735518B2/en not_active Expired - Fee Related
- 2010-10-06 AR ARP100103629A patent/AR078536A1/en unknown
- 2010-10-06 IN IN2556DEN2012 patent/IN2012DN02556A/en unknown
- 2010-10-06 TW TW099133977A patent/TW201124409A/en unknown
- 2010-10-06 ES ES10760729T patent/ES2737429T3/en active Active
- 2010-10-06 WO PCT/EP2010/064941 patent/WO2011042475A1/en active Application Filing
- 2010-10-06 AR ARP100103631A patent/AR078538A1/en unknown
- 2010-10-06 CN CN201080055575.3A patent/CN102648183B/en not_active Expired - Fee Related
- 2010-10-06 TW TW099133976A patent/TW201124406A/en unknown
-
2014
- 2014-01-10 US US14/152,584 patent/US8921402B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2737429T3 (en) | 2020-01-14 |
CN102648183A (en) | 2012-08-22 |
WO2011042475A1 (en) | 2011-04-14 |
US20140128435A1 (en) | 2014-05-08 |
EP2486018B1 (en) | 2019-04-24 |
CN102648183B (en) | 2015-12-02 |
JP5735518B2 (en) | 2015-06-17 |
WO2011042477A1 (en) | 2011-04-14 |
AR078536A1 (en) | 2011-11-16 |
JP2013507336A (en) | 2013-03-04 |
US8653112B2 (en) | 2014-02-18 |
EP2486018A1 (en) | 2012-08-15 |
AR078538A1 (en) | 2011-11-16 |
TW201124409A (en) | 2011-07-16 |
DK2486018T3 (en) | 2019-07-29 |
TW201124406A (en) | 2011-07-16 |
US8921402B2 (en) | 2014-12-30 |
US20120202853A1 (en) | 2012-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN02556A (en) | ||
NZ588121A (en) | Novel estrogen receptor ligands | |
MX2014012695A (en) | Isoindolone derivatives. | |
UA103616C2 (en) | Substituted gamma lactams as therapeutic agents | |
MX2014001595A (en) | Indazole compounds, compositions and methods of use. | |
MY170922A (en) | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | |
MX2013006304A (en) | Glucagon analogs exhibiting gip receptor activity. | |
UA102251C2 (en) | Aminidihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease | |
GEP20146125B (en) | Aminopyrimidines as syk inhibitors | |
TN2013000253A1 (en) | Bicyclo[3.2.1]octyl amide derivatives and uses of same | |
IN2012DN00869A (en) | ||
MX2009003157A (en) | Therapeutic pyrazolyl thienopyridines. | |
MX2011012264A (en) | Bridged spiro [2.4] heptane derivatives as alx receptor and/or fprl2 agonists. | |
MX2011013016A (en) | Aminopyrrolidinone derivatives and uses thereof. | |
MX2014006026A (en) | Aminopyrimidine derivatives as lrrk2 modulators. | |
MX2009004662A (en) | Pyrazoline compounds as mineralocorticoid receptor antagonists. | |
IN2012DN03182A (en) | ||
MX2013011589A (en) | Methods and compositions for treating parkinson's disease. | |
MY169479A (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
MX353209B (en) | D2 ANTAGONISTS, METHODS OF SYNTHESIS and METHODS OF USE. | |
GB0812642D0 (en) | Compounds | |
MX2013006418A (en) | Oxazolyl-methylether derivatives as alx receptor agonists. | |
MX2013006420A (en) | Hydroxylated aminotriazole derivatives as alx receptor agonists. | |
MX2012001617A (en) | N1-substituted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives. | |
IN2012DN02502A (en) |